RCUS News and Press, Arcus Biosciences Inc. From 12/24/23

2023-12-24 01:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-15 02:25:57 ET Summary Arcus Biosciences is developing a combination therapy of PD-1 and TIGIT inhibitors for esophagogastric cancer, showing promising efficacy in a phase 2 study. The company's most advanced molecule, domvanalimab, is being investigated in lung cancer and...

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – Exelixis, Inc. (Nasdaq:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 tr...

2023-11-20 14:19:50 ET Summary Domvanalimab, Arcus Biosciences’ Phase 3 cancer immunotherapy drug, shows promise in treating lung and gastrointestinal cancers, but faces a competitive anti-TIGIT market. Arcus experienced a slight revenue drop and increased net loss in Q3 20...

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming 6 th Annual Evercore ISI He...

2023-11-08 00:54:08 ET Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Conference Call November 07, 2023, 05:00 PM ET Company Participants Pia Eaves - Head of Investor Relations And Strategy Terry Rosen - Co-Founder, Chairman & CEO Dimitry Nuyten - Chief Medi...

2023-11-07 16:24:11 ET Arcus Biosciences press release ( NYSE: RCUS ): Q3 GAAP EPS of -$0.94 beats by $0.19 . Revenue of $32M (-3.0% Y/Y) beats by $4.44M . $950 million in cash, cash equivalents and marketable securities and funding expected into 2026. Fo...

Data were presented from the ongoing EDGE-Gastric Phase 2 study in first-line upper GI cancers at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Plenary Series; domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the poten...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Arcus Biosciences Inc. (RCUS) is expected to report $-1.12 for Q3 2023